Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Bone Marrow Transplant

Rituximab for Patients Undergoing SCT for Relapsed B-Cell Cancer (FHCRC-2226)
Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Relapsed or Refractory CD20+ B-Cell Malignancies
Status Conditions Phase Study ID
Recruiting Graft Versus Host Disease
Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Precancerous Condition
Small Intestine Cancer
Phase II FHCRC-2226
Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cell-killing substances to them. Giving rituximab before and after donor stem cell transplant may kill more hematologic cancer cells.

PURPOSE: This phase II trial is studying rituximab in treating patients undergoing stem cell transplant for B-cell cancer that has relapsed or not responded to treatment.


Investigator
Andrew Rezvani, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of CD20-expressing B-cell malignancy

    • Any histologic type or grade for which nonmyeloablative allogeneic transplantation is considered an appropriate treatment option
    • Relapsed or refractory disease
  • Concurrently enrolled on a nonmyeloablative allogeneic hematopoietic cell transplantation protocol treatment plan employing total body irradiation (TBI)-based conditioning of ≤ 4 Gy, with or without fludarabine

    • Studies may include, but are not limited to, the following:

      • FHCRC-1813.00
      • FHCRC-1938.00
      • FHCRC-1898.00
      • FHCRC-1409.00
    • Receiving unmodified peripheral blood mononuclear cell graft products
    • Must have appropriate related or unrelated donor available (no HLA-haploidentical donors)
    • No protocols involving bone marrow allografts

PATIENT CHARACTERISTICS:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for ≥ 12 months after completion of study treatment

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • Enrollment in protocol FHCRC-1726.00 takes priority over this study for patients with chemorefractory aggressive non-Hodgkin lymphoma
  • Enrollment in protocol FHCRC-1711.00 or FHCRC-1840.00 takes priority over this study for patients with chronic lymphocytic leukemia
Last Updated
May 26, 2010
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.